Immunotherapy

 

The immune system is a system of cells and organs whose function is to defend an organism from foreign pathogens. With the ability to mount a response against virtually any foreign material and return to a quiescent state following neutralization of the threat, this fascinating organ system displays remarkable specificity and plasticity. To achieve this, there is a multifaceted balancing act between the many activators and suppressors that maintains homeostasis of perhaps the body’s most complex organ system.

Activation of the immune system involves a number of checkpoints in order to ensure proper activation. For instance, T cell activation requires binding of the T cell receptor to the MHC antigen, yet this interaction alone is not sufficient for producing a T cell response. Full T cell activation and inactivation requires the coordination of a multitude of co-stimulatory and inhibitory signals. For example, T cell activation can result from the combination of MHC:TCR and B7-1:CD28 interaction. In contrast, B7-1 binding to CTLA4 results in an inhibitory signal that prevents activation.

Given its diverse function and the fact that the immune system plays a role in virtually all human diseases, immunotherapy has become an important approach for the treatment of numerous diseases. Immunotherapy is defined as the treatment of disease by inducing, enhancing, or suppressing an immune response. This often involves targeting immunoreceptors, such as those discussed above, with small molecule inhibitors/activators or immune system components, including antibodies or antibody fragments (Fab). Immunotherapies have shown efficacy in the treatment of cancer, autoimmune diseases, inflammatory diseases, and more.

BPS Bioscience offers many purified, soluble immunoreceptors involved in key immunosignaling pathways. Additionally, we offer a number of assay kits that can be used to screen for inhibitors of protein-protein interaction, as well as neutralizing antibodies to serve as positive controls for inhibition.

References:

1.  Pardoll, D.M., Nat. Rev. Cancer. 2012; 12: 252-264.
2.  Lesterhuis, W.J., et al., Nat. Rev. Drug. Disc. 2011; 10: 591-600.

Immunotherapy Subcategories

Items 26 to 50 of 430 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Catalog#SizeProduct NamePrice
71219 100 µg Anti-LAG3, Neutralizing Antibody
$475
72063-1 50 µg Anti-OX40 Antagonist Antibody
$335
72063-2 100 µg Anti-OX40 Antagonist Antibody
$475
72064-2 100 µg Anti-OX40 Antibody, PE-Labeled
$495
72064-1 50 µg Anti-OX40 Antibody, PE-Labeled
$345
72558-1 50 μg Anti-OX40 Competitive Antibody
$335
71326 100 µg Anti-PD-1 (S228P) Neutralizing Antibody
$475
71120 100 µg Anti-PD-1 Neutralizing Antibody
$475
71215 100 µg Anti-PD-1 Neutralizing Antibody, Biotin-labeled
$495
71290-2 100 ug Anti-PD-1 Neutralizing Antibody, PE-labeled
$495
71213 100 µg Anti-PD-L1 (CD274) Neutralizing Antibody
$475
71128-2 100 μg Anti-PD-L1 Antibody, PE-labeled
$495
71128-1 50 μg Anti-PD-L1 Antibody, PE-labeled
$345
71214 100 µg Anti-PD-L1 Neutralizing Antibody, Biotin-labeled
$495
71228-1 50 μg Anti-TIGIT Antibody, PE-Labeled
$345
71228-2 100 μg Anti-TIGIT Antibody, PE-Labeled
$495
71218 100 µg Anti-TIGIT Inhibitor Antibody
$475
71340 100 μg Anti-TIGIT Neutralizing Antibody
$475
71121-2 100 µg Anti-TIM-3 Antibody, PE-Labeled
$495
71121-1 50 µg Anti-TIM-3 Antibody, PE-Labeled
$345
72048 384 reactions ARG1 Inhibitor Screening Assay Kit
$1,095
71658 50 μg ARG1, His-Tag
$455
71659 50 μg ARG2, His-Tag
$455
71125 100 µg B7-1 (CD80), Fc fusion (Human) HiP™
$310
71114 50 µg B7-1 (CD80), Fc fusion, Biotin-labeled (Human) HiP™
$405

Items 26 to 50 of 430 total

per page
Page:
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5